Implementing a monitoring program for patients on direct oral
anticoagulants
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Service

Adaptability

DOAC Monitoring Checklists

• Backus Hospital Medication Management Clinic located in Norwich, CT
provides a newly implemented Direct Oral Anticoagulant (DOAC)
management service.
• Patient population: patients with non-valvular atrial fibrillation or venous
thromboembolism
• Role of clinical pharmacist:
• Initiation of DOAC therapy
• Monitors for the efficacy and safety of DOAC therapy
• Provides education on the benefits and risks of DOAC therapy
• Pharmacist Evaluation:
• Lifestyle (diet and exercise)
• Renal function
• Drug-drug interactions and other medications use
• Clinical pharmacist communicates to the referring physicians on any
significant concerns or recommendations with DOAC therapy.
• The referred patients will be discharged from the clinic when they have
been on DOAC for an extended duration (typically >6 months).
• Prior to discharge, the patients will be assessed to ensure that they are welleducated on signs and symptoms of adverse events to DOAC agents and
what actions to take if these events were to arise.

• DOAC management service can be implemented in pharmacist-driven
anticoagulation clinics.
• Many anticoagulation clinics are already staffed with healthcare
professionals, who are well trained at evaluating and educating patients for
the signs and symptoms of thrombosis and bleeding.
• The same concept along with renal function monitoring is applied in this
DOAC management program.

The “ABCDEF” of direct oral anticoagulant management

Justification
• Many providers choose a DOAC for anticoagulation because of the ease of
administration and fewer drug and food interactions.
• A number of providers, however, forego any follow-up with patients on
DOAC agents believing it is unwarranted.
• On the contrary, a growing body of evidence and expert opinion supports
the importance of follow-up monitoring for these patients.
• Pharmacist interventions:
• Patients’ adherence
• Monitoring for adverse events
• Improve health outcomes

Significance
• The role of a clinical pharmacist is expanding rapidly in the healthcare world
in which the pharmacist is gaining more responsibilities as a valuable
member of a healthcare team. Since the use of DOACs is on the rise, DOAC
management program driven by pharmacist will enhance patient care and
safety along with expanding the pharmacist’s role in anticoagulation care.

Referral System
1.Diagnosis
a. Non-valvular atrial fibrillation (NVAF)
b. Venous thromboembolism (VTE)
2.Direct Oral Anticoagulant of Choice
Class
Dosing

Pradaxa® (dabigatran)
Direct thrombin (IIa)
inhibitor
NVAF: 150 mg BID
DVT/PE: 150 mg BID
after 5 to 10 days of
parenteral
anticoagulation

Xarelto® (rivaroxaban)
Direct Factor Xa
inhibitor
NVAF: 20 mg daily
DVT/PE: 15 mg BID x 21
days, then 20 mg daily

Eliquis® (apixaban)
Direct Factor Xa
inhibitor
NVAF: 5 mg BID
DVT/PE: 10 mg BID x 7
days, then 5 mg BID

Savaysa® (edoxaban)
Direct Factor Xa
inhibitor
NVAF: 60 mg daily
DVT/PE: 60 mg daily
after 5 to 10 days of
parenteral
anticoagulation

3.Duration of Anticoagulation Therapy
a. Indefinite, 3 months, 6 months, or 1 year
4.Other Anticoagulation Status
a. Current use of oral anticoagulant or LMWH
5.Relevant Past Medical History
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